| abstract |
Composition comprising a pharmaceutically acceptable carrier and a compound of formula V: (See formula) or a pharmaceutically acceptable salt, in which; Z1 is N, CRa, or CH and Z2 is N or CH, provided that only one of Z1 and Z2 is nitrogen; G is ring C or ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, wherein said C ring has one or two ortho substituents independently selected from -R1, any position of non-ortho carbon in ring C is optionally and independently substituted by -R5, and two adjacent substituents in ring C are optionally taken together with their intervening atoms to form a 5-6-membered, unsaturated or partially unsaturated condensed ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, said condensed ring being optionally substituted by halogen, oxo, or -R8; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 heteroatoms of nitrogen, oxygen or sulfur selected heteroatoms, wherein the D ring is substituted on any ring carbon that can be substituted by oxo or -R5, and on any ring nitrogen that can be substituted by -R4, provided that the D ring is a six-membered aryl or heteroaryl ring , -R5 is hydrogen at each ortho carbon position of ring D; R1 is selected from halogen, -CN, -NO2, TV-R6, phenyl, 5-6 membered heteroaryl ring, 5-6 membered heterocyclyl ring, or C 1-6 aliphatic group, said phenyl ring being, heteroaryl, and heterocyclyl each optionally substituted by up to three independently selected groups of halogen, oxo, or -R8, said C1_6 aliphatic group being optionally substituted with halogen, cyano, nitro, or oxygen, or R1 and an adjacent substituent taken together with their the atoms that intervene form said ring fused to ring C; Rx and Ry are independently selected from T-R3, or Rx and Ry are taken together with their intervening atoms to form a condensed, unsaturated or partially unsaturated, 5-8-membered ring that has 0-3 ring heteroatoms selected from oxygen , sulfur, or nitrogen, in which any carbon that can be substituted in said condensed ring formed by Rx and Ry is substituted by oxo or T-R3, and any nitrogen that can be substituted in said ring formed by Rx and Ry is substituted by R4 ; T is a valence bond or a C1_4 alkylidene chain; R2 and R2 '' are independently selected from -R,, -TW-R6, or R2 and R2 ~ are taken together with their intervening atoms to form a condensed ring, 5-8 members, unsaturated or partially unsaturated, which has 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, in which each carbon that can be substituted in said fused ring consisting of R2 and R2 ~ is substituted by halogen, oxo, -CN, -NO2, -R7, or - V-R6, and any nitrogen that can be substituted in said ring formed by R2 and R2 '' is substituted by R4; R3 is selected from -R, halogen, -OR, -C (= O) R, -CO2R, -COCOR, -COCH2COR, -NO2, -CN, -S (O) R, -S (O) 2 R, -SR, -N (R4) 2, -CON (R7) 2, -SO2N (R7) 2, -OC (= O) R, -N (R7) COR, -N (R7) CO2 (C1_6 aliphatic group optionally substituted), -N (R4) N (R4) 2, -C = NN (R4) 2, -C = N-OR, -N (R7) CON (R7) 2, -N (R7) SO2N (R7) 2, -N (R4) SO2R, or -OC (= O) N (R7) 2; each R is independently selected from hydrogen or an optionally substituted group selected from C1_66 aliphatic group, C6_10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms. |